Immunotherapy for hepatobiliary cancers: Emerging targets and translational advances
Authors:
- 18 February 2022
- book chapter
- Published by Elsevier
- Vol. 156, 415-449
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- U.S. Department of Health and Human Services
- National Cancer Institute (Z01 BC010891)
This publication has 124 references indexed in Scilit:
- Mesothelin Binding to CA125/MUC16 Promotes Pancreatic Cancer Cell Motility and Invasion via MMP-7 ActivationScientific Reports, 2013
- Crystal Structure of N-Glycosylated Human Glypican-1 Core ProteinJournal of Biological Chemistry, 2012
- Structure of the protein core of the glypican Dally-like and localization of a region important for hedgehog signalingProceedings of the National Academy of Sciences, 2011
- Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinomaBritish Journal of Cancer, 2011
- A novel high‐affinity human monoclonal antibody to mesothelinInternational Journal of Cancer, 2011
- Glypican-3: A new target for cancer immunotherapyEuropean Journal of Cancer, 2011
- Overgrowth of a mouse model of Simpson– Golabi–Behmel syndrome is partly mediated by Indian HedgehogEMBO Reports, 2009
- A Binding Domain on Mesothelin for CA125/MUC16Journal of Biological Chemistry, 2009
- Mesothelin targeted cancer immunotherapyEuropean Journal of Cancer, 2008
- Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell ResponsesImmunity, 2007